Aclaris Therapeutics Inc to Post FY2019 Earnings of ($2.98) Per Share, William Blair Forecasts (ACRS)

Aclaris Therapeutics Inc (NASDAQ:ACRS) – Analysts at William Blair lowered their FY2019 EPS estimates for shares of Aclaris Therapeutics in a research report issued to clients and investors on Monday, March 18th. William Blair analyst T. Lugo now forecasts that the biotechnology company will post earnings of ($2.98) per share for the year, down from their prior estimate of ($2.93). William Blair also issued estimates for Aclaris Therapeutics’ FY2020 earnings at ($2.67) EPS.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Monday, March 18th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by ($0.03). The company had revenue of $3.67 million for the quarter, compared to the consensus estimate of $4.40 million. Aclaris Therapeutics had a negative return on equity of 72.13% and a negative net margin of 1,315.41%.

A number of other analysts also recently weighed in on the company. BidaskClub upgraded Aclaris Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, December 1st. Zacks Investment Research upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Tuesday, December 4th. ValuEngine downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 2nd. Finally, Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the stock a “buy” rating in a report on Friday, December 28th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $35.94.

Shares of NASDAQ:ACRS opened at $6.27 on Thursday. The firm has a market cap of $285.17 million, a P/E ratio of -1.56 and a beta of 1.24. The company has a debt-to-equity ratio of 0.14, a current ratio of 6.57 and a quick ratio of 6.48. Aclaris Therapeutics has a 12-month low of $5.49 and a 12-month high of $21.97.

A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. grew its holdings in Aclaris Therapeutics by 43.8% during the 4th quarter. BlackRock Inc. now owns 3,620,835 shares of the biotechnology company’s stock worth $26,759,000 after acquiring an additional 1,103,423 shares during the period. D. E. Shaw & Co. Inc. grew its holdings in Aclaris Therapeutics by 71.6% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 2,278,364 shares of the biotechnology company’s stock worth $16,837,000 after acquiring an additional 950,781 shares during the period. Sofinnova Investments Inc. grew its holdings in Aclaris Therapeutics by 24.2% during the 4th quarter. Sofinnova Investments Inc. now owns 1,911,573 shares of the biotechnology company’s stock worth $14,127,000 after acquiring an additional 372,093 shares during the period. Broadfin Capital LLC acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at about $13,875,000. Finally, MFN Partners Management LP acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at about $11,085,000. Hedge funds and other institutional investors own 94.97% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Featured Article: What are no-load funds?

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.